The introduction of novel agents thalidomide, lenalidomide, and the proteasome inhibitor bortezomib, has dramatically improved the outcome of multiple myeloma and today various effective treatment options are available. Both young and elderly patients with multiple myeloma showed to benefit from sequential approaches including novel agents. In young patients, commonly eligible for transplantation, novel combinations as induction before transplantation led to deeper and long-lasting response, and improved survival. Elderly patients or patients with comorbidities would not tolerate high-dose therapy and transplantation, thus gentler approaches are needed. Also in these patients, novel agents have revolutionized the traditional treatment and new effective approaches are now used.
Multiple myeloma
Mina R.;Palumbo A.
2015-01-01
Abstract
The introduction of novel agents thalidomide, lenalidomide, and the proteasome inhibitor bortezomib, has dramatically improved the outcome of multiple myeloma and today various effective treatment options are available. Both young and elderly patients with multiple myeloma showed to benefit from sequential approaches including novel agents. In young patients, commonly eligible for transplantation, novel combinations as induction before transplantation led to deeper and long-lasting response, and improved survival. Elderly patients or patients with comorbidities would not tolerate high-dose therapy and transplantation, thus gentler approaches are needed. Also in these patients, novel agents have revolutionized the traditional treatment and new effective approaches are now used.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
